CFAP157: A Potential Drug Target for Cancer and Cellular Signaling

Target Name: CFAP157

NCBI ID: G286207

CFAP157

CFAP157: A Potential Drug Target for Cancer and Cellular Signaling

Cilia- and flagella-associated protein 157 (CFAP157) is a protein that is expressed in the cilium and flagellum, which are structures found in the cytoskeleton of eukaryotic cells. The cilium and flagellum are composed of a series of microtubules that are involved in the movement of cells, and they play a crucial role in the process of cell division and transport of organelles within the cell.

CFAP157 is a member of the protein family known as the myosin-associated protein (MAP) family. This family of proteins is characterized by the presence of a unique catalytic domain in the N-terminus that is involved in the formation of a covalent complex with the protein myosin. This interaction between MAPs and myosins is thought to play a role in the regulation of cellular processes such as muscle contraction and cytoskeletal dynamics.

CFAP157 is expressed in a variety of tissues and cells, including muscle, liver, and brain cells. It is also highly expressed in cancer cells, which may make it an attractive drug target or biomarker for cancer therapies. In fact, several studies have suggested that CFAP157 may be a potential therapeutic target for various types of cancer, including breast, ovarian, and colorectal cancer.

One of the reasons why CFAP157 may be a drug target is its role in the regulation of cellular signaling pathways. It has been shown to be involved in a number of signaling pathways that are involved in cell growth, differentiation, and survival. For example, studies have suggested that CFAP157 may be involved in the regulation of the Notch signaling pathway, which is involved in the regulation of stem cell self-renewal and differentiation.

In addition to its role in signaling pathways, CFAP157 has also been shown to be involved in the regulation of cellular structure and cytoskeletal dynamics. It is a protein that is involved in the formation of the cytoskeleton, and it has been shown to play a role in the regulation of microtubule dynamics and stability.

Another potential reason why CFAP157 may be a drug target is its role in the regulation of cell death. It has been shown to be involved in the regulation of cell death, which is a critical aspect of cellular signaling pathways. This is because CFAP157 has been shown to be involved in the formation of the mitochondrial outer membrane (MOM) pore, which is involved in the delivery of oxygen to the cell's cytoplasm.

In conclusion, CFAP157 is a protein that is expressed in a variety of tissues and cells, and it is involved in a number of cellular processes that are important for cell growth, differentiation, and survival. Its role in the regulation of cellular signaling pathways and cytoskeletal dynamics, as well as its involvement in the regulation of cell death, make it an attractive drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of CFAP157 in cellular processes and its potential as a therapeutic target .

Protein Name: Cilia And Flagella Associated Protein 157

Functions: Specifically required during spermatogenesis for flagellum morphogenesis and sperm motility. May be required to suppress the formation of supernumerary axonemes and ensure a correct ultrastructure

The "CFAP157 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP157 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets